• Mangoceuticals partnered with T7X to issue tokenized preferred stock natively on-chain, potentially becoming the first Nasdaq-listed issuer on the platform.
• Up to 1,000,000 Series D Cumulative Convertible Preferred Stock shares at $10 each would raise $10 million, subject to SEC qualification.
• The preferred stock carries 8% cumulative, noncompounding annual dividends, payable quarterly in cash when declared by the board.
• No common stock will be issued at closing; proceeds will fund general corporate purposes and working capital.
• Conversion begins three years after issuance at 300% of the 10-trading-day pre-qualification volume-weighted average Nasdaq closing price, subject to a floor.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mangoceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120700PRIMZONEFULLFEED9876159) on November 12, 2026, and is solely responsible for the information contained therein.